Efficacy and Safety of Angong Niuhuang Pill in Patients With Acute Ischemic Stroke

Affiliated Hangzhou First People's Hospital, Xihu University School of Medicine0 个研究点开始时间: 待定最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1.Being 18 years of age or older; 2.Having experienced an acute ischemic stroke; 3.Being within 24 hours of stroke onset or last-seen well; 4.Having a National Institutes of Health Stroke Scale (NIHSS) score of at least 6 before entering the trial; 5.Undergoing multimodal imaging assessment where CT artery (CTA) confirmed that the stroke was caused by occlusion of a large vessel in the anterior circulation; 6.The patients or their legal representatives providing signed informed consent.

•1.NCCT suggests intracranial hemorrhage;
•2.Active bleeding or a significant bleeding tendency;
•3.Patients with renal failure, serum creatinine =264umol/L;
•4.pre-existing mRS=2;
•5.previous allergy to contrast media; Allergic to known ingredients of Angong Niuhuang pills;
•6.Multiple organ failure, can not tolerate surgery
•7.The expected survival time of other diseases (such as malignant tumors) is less than 3 months

发起方

Affiliated Hangzhou First People's Hospital, Xihu University School of Medicine